Randomised Phase III Trial of Carboplatin Plus Etoposide Vs Split Doses of Cisplatin Plus Etoposide in Elderly or Poor-risk Patients with Extensive Disease Small-cell Lung Cancer: JCOG 9702

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Jun 21

PMID 17579629

Citations 76

Authors

H Okamoto

K Watanabe

H Kunikane

A Yokoyama

S Kudoh

T Asakawa

T Shibata

H Kunitoh

T Tamura

N Saijo

Affiliations

Soon will be listed here.

Abstract

We compared the efficacy and the safety of a carboplatin plus etoposide regimen (CE) vs split doses of cisplatin plus etoposide (SPE) in elderly or poor-risk patients with extensive disease small-cell lung cancer (ED-SCLC). Eligibility criteria included: untreated ED-SCLC; age >/=70 and performance status 0-2, or age <70 and PS 3. The CE arm received carboplatin area under the curve of five intravenously (IV) on day 1 and etoposide 80 mg m(-2) IV on days 1-3. The SPE arm received cisplatin 25 mg m(-2) IV on days 1-3 and etoposide 80 mg m(-2) IV on days 1-3. Both regimens were given with granulocyte colony-stimulating factor support in a 21-28 day cycle for four courses. A total of 220 patients were randomised. Median age was 74 years and 74% had a PS of 0 or 1. Major grade 3-4 toxicities were (%CE/%SPE): leucopenia 54/51, neutropenia 95/90, thrombocytopenia 56/16, infection 7/6. There was no significant difference (CE/SPE) in the response rate (73/73%) and overall survival (median 10.6/9.9 mo; P=0.54). Palliation scores were very similar between the arms. Although the SPE regimen is still considered to be the standard treatment in elderly or poor-risk patients with ED-SCLC, the CE regimen can be an alternative for this population considering the risk-benefit balance.

Citing Articles

Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.

Zhao K, Lu S, Niu J, Zhu H, Tian Y, Yu J BMC Cancer. 2025; 25(1):467.

PMID: 40087602 DOI: 10.1186/s12885-025-13880-z.

Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study.

Misawa K, Watanabe K, Seike M, Hosomi Y Transl Lung Cancer Res. 2024; 13(7):1585-1594.

PMID: 39118881 PMC: 11304155. DOI: 10.21037/tlcr-24-128.

Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer.

Tsukazaki Y, Ogino H, Okano Y, Kakiuchi S, Harada S, Toyoda Y Int J Clin Oncol. 2024; 29(10):1451-1460.

PMID: 39009900 DOI: 10.1007/s10147-024-02586-0.

Therapeutic Patterns and Clinical Outcomes in Limited Disease Small Cell Lung Cancer: A Decade of Analysis at a Tertiary Cancer Center.

Ziegler D, Cleve C, Ziegler S, Schirmer M, Fischer L, Bohnenberger H Cancers (Basel). 2024; 16(11).

PMID: 38893074 PMC: 11171404. DOI: 10.3390/cancers16111953.

Oncogenic alterations in advanced NSCLC: a molecular super-highway.

Friedlaender A, Perol M, Banna G, Parikh K, Addeo A Biomark Res. 2024; 12(1):24.

PMID: 38347643 PMC: 10863183. DOI: 10.1186/s40364-024-00566-0.

References

Go R, Adjei A . Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17(1):409-22. DOI: 10.1200/JCO.1999.17.1.409. View

Samantas E, Skarlos D, Pectasides D, Nicolaides P, Kalofonos H, Mylonakis N . Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer. Lung Cancer. 1999; 23(2):159-68. DOI: 10.1016/s0169-5002(98)00095-6. View

Niell H, Herndon 2nd J, Miller A, Watson D, Sandler A, Kelly K . Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005; 23(16):3752-9. DOI: 10.1200/JCO.2005.09.071. View

Timmer-Bonte J, De Boo T, Smit H, Biesma B, Wilschut F, Cheragwandi S . Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005; 23(31):7974-84. DOI: 10.1200/JCO.2004.00.7955. View

Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage J, Balducci L . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19):3187-205. DOI: 10.1200/JCO.2006.06.4451. View

Okamoto H, Naoki K, Narita Y, Hida N, Kunikane H, Watanabe K . A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer. Lung Cancer. 2006; 53(2):197-203. DOI: 10.1016/j.lungcan.2006.05.004. View

Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I . Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999; 17(11):3540-5. DOI: 10.1200/JCO.1999.17.11.3540. View

Yuen A, Zou G, Turrisi A, Sause W, Komaki R, Wagner H . Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer. 2000; 89(9):1953-60. DOI: 10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y. View

Quoix E, Breton J, Daniel C, Jacoulet P, Debieuvre D, Paillot N . Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. Ann Oncol. 2001; 12(7):957-62. DOI: 10.1023/a:1011171722175. View

10.

Larive S, Bombaron P, Riou R, Fournel P, Perol M, Lena H . Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer. 2001; 35(1):1-7. DOI: 10.1016/s0169-5002(01)00288-4. View

11.

Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A . Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346(2):85-91. DOI: 10.1056/NEJMoa003034. View

12.

Morita T . A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res. 2002; 93(1):15-23. PMC: 5926863. DOI: 10.1111/j.1349-7006.2002.tb01195.x. View

13.

Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M . Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22(19):3852-9. DOI: 10.1200/JCO.2004.02.109. View

14.

Schoenfeld D, Richter J . Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982; 38(1):163-70. View

15.

Findlay M, Griffin A, Raghavan D, McDonald K, Coates A, Duval P . Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means?. Eur J Cancer. 1991; 27(12):1597-601. DOI: 10.1016/0277-5379(91)90422-a. View

16.

Radford J, Ryder W, Dodwell D, Anderson H, Thatcher N . Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer. 1992; 29A(1):81-6. DOI: 10.1016/0959-8049(93)90581-y. View

17.

Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K . Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993; 23(4):250-7. View

18.

Maksymiuk A, Jett J, Earle J, Su J, Diegert F, Mailliard J . Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994; 12(1):70-6. DOI: 10.1200/JCO.1994.12.1.70. View

19.

DeMets D, Lan K . Interim analysis: the alpha spending function approach. Stat Med. 1994; 13(13-14):1341-52; discussion 1353-6. DOI: 10.1002/sim.4780131308. View

20.

Evans W, Radwi A, Tomiak E, LOGAN D, Martins H, Stewart D . Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol. 1995; 18(2):149-55. View